This website is intended for healthcare professionals only and contains promotional content.

Report an adverse event here
Link Logo
United Kingdom - English

United Kingdom - English

United Kingdom | English

These country specific websites are specifically intended for healthcare professionals in listed countries only.

Europe

Deutschland - DeutschDeutschland - Deutsch España - EspañolEspaña - Español Italia - ItalianoItalia - Italiano United Kingdom - EnglishUnited Kingdom - English

NOTICE: Kyowa Kirin International has agreed a joint venture with Grünenthal GmbH for the Established Medicines portfolio. The new company, KKI NewCo (known as Grünenthal Meds), is responsible for the content on this page. For more information please click here.​

MASCC Webinar Expert Videos

A series of videos from the MASCC (Multinational Association of Supportive Care in Cancer) virtual meeting. Featuring presentations from experts in opioid induced constipation, Dr. Antoine Lemaire, Dr. Andrew Davies, Dr. Carmen Beato and Dr. Francesca Caputo.

Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse Events should also be reported to Kyowa Kirin International UK NewCo Ltd, known as Grünenthal Meds on +44 (0)1896 664000, email PVUK@grunenthalmeds.com

Dr. Lemaire - Opioid-induced constipation: from consensus guidelines to clinical practice

Dr. Davies - Opioid-induced constipation in the "real world": StOIC studies

Dr. Beato - KYONAL: evaluation of the quality of life of patients with OIC following naloxegol administration

MOVENTIG (naloxegol) is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). For advice on the responsible use of opioids to treat pain, please click here

Average: